Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{167864,
        author = {JAYA LAXMI.K and SUDHEER.U and SRIDEVI.P},
        title = {A Review on Quality by Design (QbD)},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {4},
        pages = {616-625},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=167864},
        abstract = {In this Review, we have done extensive literature on Quality by Design. ICH guidelines Q8 (pharmaceutical development), Q9 (quality risk management) and Q10 (quality systems) forms the basis of QbD. QbD defines the quality target product profile (QTPP), critical quality attributes (CQA), risk assessment and life cycle management to design and develops the formulation and process. This review provides overview of the modern pharmaceutical quality by design (QbD), clarifies the concept and describes its objectives. It is a cost and time efficient approach in design and manufacturing, with DoE, risk assessment, and PAT as its tools to achieve a better understanding on the materials and processes, which make the QbD approach available and feasible to the pharmaceutical field. It also gives application of Quality by Design in pharmaceutical development and manufacturing of pharmaceuticals.},
        keywords = {Critical Quality Attributes (CQA), Design Space (DS), Design of experiment (DoE), Process analytical technologies (PAT), Quality by design (QbD), Quality Target Product Profile (QTPP), Quality risk management (QRM)},
        month = {September},
        }